Publications

Journal Article
Research Support, Non-U.S. Gov't
Ppublish 27 citations
Electronic publication date
June 10, 2008

View on Pubmed.gov 18367440 | View on doi.org 10.1007/BF03033...

Huperzine A provides neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death.

Search for publications in this journal Neurotox Res - 13(1):49-61

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting from the progressive loss of motor neurons in the spinal cord and brain. To date, clinically effective neuroprotective agents have not been available. The current study demonstrates for the first time that huperzine A, a potential neuroprotective agent, has the ability to protect a motor neuron-like cell line and motor neurons in spinal cord organotypic cultures from toxin-induced cell death. The neuroblastoma-spinal motor neuron fusion cell line, NSC34 and rat spinal cord organotypic cultures (OTC) were exposed to cell death inducers for 24 h or 14 d, respectively, with and without pre-treatment with huperzine A. The inducers used here include: staurosporine, thapsigargin, hydrogen peroxide (H2O2), carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and L-(-)-threo-3-hydroxyaspartic acid (THA). These agents were selected as they induce apoptosis/necrosis via mechanisms implicated in patients with generalized motor neuron disease. Cell death was determined in NSC34 cells by metabolic activity, caspase activity/expression and by nuclear morphology and in the OTCs, using immunohistochemistry and Western blot analysis. Nuclear staining of NSC34 cells revealed cell death induced by staurosporine, thapsigargin, H2O2 and CCCP. This induction was significantly reduced with 2 h pre-treatment with 10 microM huperzine A (maximum, 35% rescue; p 0.05) following exposure to staurosporine, thapsigargin and H2O2 but not with CCCP. These data were supported by the metabolic assays and caspase activity. In addition, pre-treatment with huperzine A dramatically improved motor neuron survival, based on choline acetyltransferase (ChAT) expression analysis in OTCs following exposure to THA, and compared to THA-treated control cultures. These studies are currently being extended to include other inducers and with additional compounds as potential drug therapies that could be used in combination for the treatment of patients with ALS.

References

Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6591-5

J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1046-57

Exp Neurol. 2005 Dec;196 (2):235-43

Biochem Pharmacol. 2005 Aug 1;70(3):470-80

Cited by 27 citations (total)

Journal Article Review

Nutraceuticals and phytotherapeutics for holistic management of amyotrophic lateral sclerosis.

Electronic publication date January 31, 2023

Search for publications in this journal 3 Biotech

Deepti Katiyar [...] Parul Grover et al.

Amyotrophic lateral sclerosis" (ALS) is a progressive neuronal disorder that affects sensory neurons in the brain and spinal cord, causing...

Journal Article

Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Mutant Mice.

Electronic publication date November 2, 2016

Search for publications in this journal Front Pharmacol

Jennifer C Wong [...] Andrew Escayg et al.

loss-of-function mutations in the voltage-gated sodium channel (VGSC) (encoding Na1.1) are the main cause of Dravet syndrome (DS), a...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances